Questions of discovery and efficacy are pivotal in patenting new products, as Editha Hechanova and Fe Belen Bello explain.
On February 15, 2012, the Intellectual Property Offce of the Philippines (IPPHL) published on its website its Examination Guidelines for Pharmaceutical Patent Applications Involving Known Substances.
These guidelines were issued pursuant to the amendments in the patent law and its implementing rules and regulations, brought about by Republic Act No. 9502, the Universally Accessible Cheaper and Quality Medicines Act of 2008 (QUAMA).
The aim of this act is to promote and ensure access to affordable quality drugs and medicines for all, pursuant to the state’s policy of protecting public health.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
efficacy, pharmaceuticals, QUAMA, patent applications
